Catalent, Inc. (CTLT)

$55.8

-0.15

(-0.27%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Catalent, Inc.

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 35.3% return, outperforming this stock by 7.4%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 40.7% return, outperforming this stock by 92.3%

Performance

  • $55.75
    $56.12
    $55.80
    downward going graph

    0.09%

    Downside

    Day's Volatility :0.66%

    Upside

    0.57%

    downward going graph
  • $31.45
    $60.20
    $55.80
    downward going graph

    43.64%

    Downside

    52 Weeks Volatility :47.76%

    Upside

    7.31%

    downward going graph

Returns

PeriodCatalent, Inc.Sector (Health Care)S&P500
3 Months
10.99%
1.1%
3.7%
6 Months
41.9%
12.5%
22.6%
1 Year
32.08%
6.9%
25.0%
3 Years
-51.64%
14.3%
21.1%

Highlights

Market Capitalization
10.1B
Book Value
$20.41
Earnings Per Share (EPS)
-7.18
PEG Ratio
2.06
Wall Street Target Price
56.7
Profit Margin
-31.77%
Operating Margin TTM
-8.01%
Return On Assets TTM
-0.75%
Return On Equity TTM
-30.28%
Revenue TTM
4.1B
Revenue Per Share TTM
22.58
Quarterly Revenue Growth YOY
-10.9%
Gross Profit TTM
1.0B
EBITDA
327.0M
Diluted Eps TTM
-7.18
Quarterly Earnings Growth YOY
-0.15
EPS Estimate Current Year
0.48
EPS Estimate Next Year
1.51
EPS Estimate Current Quarter
-0.02
EPS Estimate Next Quarter
0.24

Analyst Recommendation

Hold
    45%Buy
    50%Hold
    4%Sell
Based on 24 Wall street analysts offering stock ratings for Catalent, Inc.(by analysts ranked 0 to 5 stars)
Based on 24 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
12
Hold
12
12
11
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 1.61%

Current $55.80
Target $56.70

Company Financials

FY18Y/Y Change
Revenue
2.5B
↑ 18.7%
Net Income
83.6M
↓ 23.86%
Net Profit Margin
3.39%
↓ 1.9%
FY19Y/Y Change
Revenue
2.5B
↑ 2.22%
Net Income
137.4M
↑ 64.35%
Net Profit Margin
5.46%
↑ 2.07%
FY20Y/Y Change
Revenue
3.1B
↑ 22.89%
Net Income
221.0M
↑ 60.84%
Net Profit Margin
7.14%
↑ 1.68%
FY21Y/Y Change
Revenue
4.0B
↑ 29.21%
Net Income
585.0M
↑ 164.71%
Net Profit Margin
14.63%
↑ 7.49%
FY22Y/Y Change
Revenue
4.8B
↑ 20.76%
Net Income
499.0M
↓ 14.7%
Net Profit Margin
10.34%
↓ 4.29%
FY23Y/Y Change
Revenue
4.3B
↓ 11.43%
Net Income
-232.0M
↓ 146.49%
Net Profit Margin
-5.43%
↓ 15.77%
Q3 FY22Q/Q Change
Revenue
1.0B
↓ 22.16%
Net Income
0.0
↓ 100.0%
Net Profit Margin
0.0%
↓ 14.24%
Q4 FY22Q/Q Change
Revenue
1.1B
↑ 12.43%
Net Income
81.0M
-
Net Profit Margin
7.05%
↑ 7.05%
Q1 FY23Q/Q Change
Revenue
1.0B
↓ 9.75%
Net Income
-227.0M
↓ 380.25%
Net Profit Margin
-21.89%
↓ 28.94%
Q2 FY23Q/Q Change
Revenue
1.1B
↑ 2.99%
Net Income
-86.0M
↓ 62.11%
Net Profit Margin
-8.05%
↑ 13.84%
Q3 FY23Q/Q Change
Revenue
1.1B
↑ 0.0%
Net Income
-86.0M
↑ 0.0%
Net Profit Margin
-8.05%
↑ 0.0%
Q4 FY23Q/Q Change
Revenue
1.0B
↓ 4.12%
Net Income
-206.0M
↑ 139.53%
Net Profit Margin
-20.12%
↓ 12.07%
FY18Y/Y Change
Total Assets
4.5B
↑ 31.17%
Total Liabilities
3.4B
↑ 26.13%
FY19Y/Y Change
Total Assets
6.2B
↑ 36.48%
Total Liabilities
4.5B
↑ 30.72%
FY20Y/Y Change
Total Assets
7.8B
↑ 25.75%
Total Liabilities
4.9B
↑ 8.34%
FY21Y/Y Change
Total Assets
9.1B
↑ 17.17%
Total Liabilities
5.2B
↑ 6.55%
FY22Y/Y Change
Total Assets
10.5B
↑ 15.31%
Total Liabilities
5.7B
↑ 9.91%
FY23Y/Y Change
Total Assets
10.8B
↑ 2.62%
Total Liabilities
6.1B
↑ 7.62%
Q3 FY22Q/Q Change
Total Assets
10.2B
↓ 2.87%
Total Liabilities
5.5B
↓ 3.62%
Q4 FY22Q/Q Change
Total Assets
11.1B
↑ 9.23%
Total Liabilities
6.2B
↑ 13.26%
Q1 FY23Q/Q Change
Total Assets
10.8B
↓ 2.84%
Total Liabilities
6.1B
↓ 1.73%
Q2 FY23Q/Q Change
Total Assets
10.8B
↓ 0.44%
Total Liabilities
6.1B
↑ 0.33%
Q3 FY23Q/Q Change
Total Assets
10.8B
↑ 0.0%
Total Liabilities
6.1B
↑ 0.0%
Q4 FY23Q/Q Change
Total Assets
10.0B
↓ 7.36%
Total Liabilities
6.3B
↑ 2.51%
FY18Y/Y Change
Operating Cash Flow
374.5M
↑ 25.04%
Investing Cash Flow
-919.3M
↑ 197.51%
Financing Cash Flow
669.1M
↑ 314.82%
FY19Y/Y Change
Operating Cash Flow
247.7M
↓ 33.86%
Investing Cash Flow
-1.5B
↑ 64.3%
Financing Cash Flow
1.2B
↑ 79.55%
FY20Y/Y Change
Operating Cash Flow
440.3M
↑ 77.76%
Investing Cash Flow
-827.5M
↓ 45.21%
Financing Cash Flow
1.0B
↓ 16.62%
FY21Y/Y Change
Operating Cash Flow
433.0M
↓ 1.66%
Investing Cash Flow
-649.0M
↓ 21.57%
Financing Cash Flow
142.0M
↓ 85.82%
FY22Y/Y Change
Operating Cash Flow
439.0M
↑ 1.39%
Investing Cash Flow
-1.9B
↑ 190.29%
Financing Cash Flow
1.0B
↑ 626.06%
FY23Y/Y Change
Operating Cash Flow
261.0M
↓ 40.55%
Investing Cash Flow
-1.9B
↑ 0.0%
Financing Cash Flow
521.0M
↓ 49.47%
Q3 FY22Q/Q Change
Operating Cash Flow
-92.0M
↓ 233.33%
Investing Cash Flow
-116.0M
↓ 70.56%
Financing Cash Flow
74.0M
↑ 7300.0%
Q4 FY22Q/Q Change
Operating Cash Flow
214.0M
↓ 332.61%
Investing Cash Flow
-608.0M
↑ 424.14%
Financing Cash Flow
523.0M
↑ 606.76%
Q1 FY23Q/Q Change
Operating Cash Flow
-64.0M
↓ 129.91%
Investing Cash Flow
-110.0M
↓ 81.91%
Financing Cash Flow
-25.0M
↓ 104.78%
Q2 FY23Q/Q Change
Operating Cash Flow
203.0M
↓ 417.19%
Investing Cash Flow
-128.0M
↑ 16.36%
Financing Cash Flow
-51.0M
↑ 104.0%
Q3 FY23Q/Q Change
Operating Cash Flow
203.0M
↑ 0.0%
Investing Cash Flow
-84.0M
↓ 34.37%
Financing Cash Flow
-51.0M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Catalent, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Catalent, Inc.
Catalent, Inc.
-0.8%
41.9%
32.08%
-51.64%
25.36%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-1.55%
28.4%
35.29%
40.71%
79.5%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.71%
1.58%
-6.07%
12.69%
12.69%
Zoetis Inc.
Zoetis Inc.
-10.09%
-7.81%
-12.8%
-11.14%
48.17%
Viatris Inc.
Viatris Inc.
-2.37%
28.76%
25.82%
-14.76%
-29.31%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
56.72
56.72
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
30.04
30.04
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.5
29.5
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
225.0
225.0
NA
2.78
0.0
0.03
0.04
17.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
25.36%
211.02
-31.77%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.1B
79.5%
56.72
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.4B
12.69%
30.04
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.3B
48.17%
29.5
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.4B
-29.31%
225.0
0.35%

Institutional Holdings

  • Vanguard Group Inc

    11.17%

  • Capital World Investors

    10.56%

  • BlackRock Inc

    8.95%

  • HHG PLC

    7.33%

  • Nomura Holdings Inc

    6.36%

  • T. Rowe Price Investment Management,Inc.

    6.20%

Company Information

catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p

Organization
Catalent, Inc.
Employees
18000
CEO
Mr. Alessandro Maselli
Industry
Health Technology

Discover More

FAQs